^
    Back
    Association details:
    Biomarker:HER-2 exon 20 insertion
    Cancer:Non Small Cell Lung Cancer
    Drug:Exkivity (mobocertinib) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

    Excerpt:
    ...A HER2 exon 20 insertion; 2....
    Trial ID:
    EXCLAIM
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Curr Oncol
    Title:

    Real-World Clinical Outcomes for Patients with EGFR and HER2 Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer

    Published date:
    07/25/2023
    Excerpt:
    Among HER2 ex20ins patients, 41/47 had stage IV disease….Of the seven patients who received poziotinib, two had a partial response and five had stable disease, and the one patient who received mobocertinib had stable disease, whereas one of the four patients who received afatinib had stable disease.
    DOI:
    https://doi.org/10.3390/curroncol30080515